Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02461914
Recruitment Status : Completed
First Posted : June 3, 2015
Last Update Posted : January 24, 2017
Information provided by (Responsible Party):
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Tracking Information
First Submitted Date  ICMJE May 26, 2015
First Posted Date  ICMJE June 3, 2015
Last Update Posted Date January 24, 2017
Actual Study Start Date  ICMJE August 1, 2015
Actual Primary Completion Date December 12, 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 30, 2015)
Composite measure the plasma concentrations of warfarin [ Time Frame: Baseline to Day51 ]
Plasma concentrations of warfarin, and to calculate the pharmacokinetic parameters: Tmax、Cmax、AUC0-t、AUC0-∞、λz ,t1/2、Vd/F、CL/F etc.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02461914 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 30, 2015)
Incidence of adverse events and serious adverse events [ Time Frame: Baseline to Day78 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects
Official Title  ICMJE An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects
Brief Summary

To assess the effect of PEX168 doses on the pharmacokinetics of warfarin in healthy subjects.To provide a scientific basis for clinical drug combination of PEX168.

To evaluated the impact of pharmacodynamics coadministrated hypodermic PEX168 and warfarin in healthy subjects.

To assess the safety of single doses of warfarin administered with and without PEX168

Detailed Description

This was an open-label, sequential, single-center study that evaluated the pharmacokinetics of warfarin when coadministered with PEX168 in healthy adult subjects. The total duration of each subject's participation in the study was approximately 13 weeks, which included up to a 14-day Screening Period, a 51-day Treatment Period, and an approximately 4-week Follow-up Period.

Center: This study was conducted at a single site in the first affiliate hospital of Zhejiang University.All subjects receives a single 5mg oral dose of warfarin on Day 1 followed by 5 weekly 200μg doses of PEX168 injected subcutaneously beginning on Day 8 and a second single 5mg oral dose of warfarin on Day 44.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: PEX168
    200µg,injected subcutaneously,once a week.
    Other Name: Polyethylene Glycol Loxenatide
  • Drug: Warfarin
    5mg,oral,two times.
    Other Name: Warfarin sodium tablets
Study Arms  ICMJE Experimental: Warfaring and PEX168(200µg)
Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
  • Drug: PEX168
  • Drug: Warfarin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 30, 2015)
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 13, 2016
Actual Primary Completion Date December 12, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy male aged 18 to 45 years (including both ends) at the time of signing the informed consent.
  2. Weighing not less than 50kg,Body Mass Index (BMI)of 18 to 25kg/m2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (Tbil) are within the normal range during screening;
  3. Estimated creatinine clearance (Clcr) ≥90ml / min calculated by the Cockcroft-Gault (CG) formula ;
  4. Capable of giving written informed consent, which included compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  1. The hepatitis B surface antigen, hepatitis C antibody, HIV antibody test positive;
  2. Having history of syncope, palpitations, bradycardia, tachycardia and other anomalies, or via a comprehensive physical examination , routine laboratory tests (blood count, blood biochemistry, urine, etc.), 12-lead ECG, abdominal B ultrasound, and other abnormalities and clinical significance persons before screening;
  3. Having Alcohol and drug abuse within first 6 months before screening;
  4. Smoked within 3 months before screening;
  5. In screening period, blood pressure greater than 140 / 90mmHg, retest after diagnosis or pulse rate is higher than 100bpm person;
  6. In screening period, ECG QTc> 450ms,diagnosed after retest;
  7. Having a history of drug or allergic reactions or allergic constitution have hypersensitivity to any of the following:

1) Warfarin and / or any of its ingredients or other similar drugs . 2) PEX168

8. Before screening, having a history of cardiovascular disease or a history of pulmonary disease ;

9. The history of thromboembolic disease or undergoing surgery or gastrointestinal bleeding within 6 months before screening, or excessive bleeding or a history of heparin-induced thrombocytopenia have significant bleeding history or family history;

10.In screening period,platelet count or international normalized ratio (INR) or activated partial thromboplastin time (APTT) greater than the upper limit of the normal range or fibrinogen is less than the lower limit of the normal range;

11. In screening period , fasting triglycerides test result was greater than the upper limit of normal range;

12. Currently there is a history of liver disease or liver disease or a known hepatobiliary abnormalities (except asymptomatic gallstones);

13. Participate in blood donation and donation amount ≥400ml within three months before screening;

14. In screening period, having thyroid dysfunction or a history;

15. The history of gastrointestinal surgery before screening;

16. The history of pancreatitis;

17. History of cholecystitis gallbladder disease or other disease history;

18. The history of inflammatory bowel disease or a history of irritable bowel syndrome;

19. The history of Type 2 multiple endocrine neoplasia;

20. The history of medullary thyroid cancer;

21. The family has type 2 multiple endocrine fibromatosis or a history of medullary thyroid cancer;

22. Three months before screening, participated in any drug or medical device trials are (including placebo);

23. Using any of the tested drugs may affect prescription drugs , non-prescription drugs, herbal (especially ginseng, oral hypoglycemic agents) or multivitamin supplements persons;

24. Drinking medication or caffeine-containing xanthine food and beverage (listed in annex 3), strenuous exercise, or other effects of drug absorption, distribution, metabolism, excretion and other factors 2 days before screening.

25. Received GLP-1 analogs (e.g. exenatide) treatment;

26. Reluctant to take an effective method of contraception during the test;

27. Researchers believe any situation that might lead to any subject cannot complete the study or to the subject of this study bring significant risk.

Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT02461914
Other Study ID Numbers  ICMJE PEX168-Ii
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Jiangsu Hansoh Pharmaceutical Co., Ltd.
Study Sponsor  ICMJE Jiangsu Hansoh Pharmaceutical Co., Ltd.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Jianzhong Shentu, MD The first affiliate of Zhejiang University
PRS Account Jiangsu Hansoh Pharmaceutical Co., Ltd.
Verification Date January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP